New immune combo takes on tough pancreatic cancer

NCT ID NCT07416240

Recruiting now Disease control Sponsor: Hainan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a combination of two immune cell therapies—dendritic cells and CAR-T cells—both engineered to target a protein called Claudin18.2 found on some pancreatic cancer cells. The goal is to see if this dual approach is safe and can shrink tumors in people with advanced pancreatic cancer. Only 10 participants will be enrolled, and the main focus is on side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Claudin18.2-targeted activated dendritic cells and CAR-T cells
What this could lead to: If it works, this could point toward a new treatment option for advanced pancreatic cancer by helping the immune system attack tumors more effectively.
What could go wrong: This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The approach is complex and may not work or could cause serious side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC CANCER

Contacts and locations

Locations

Hainan Cancer Hospital
RECRUITING

Haikou, Hainan, 570311, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.